Berapa harga Freeline Therapeutics Holdings plc (FRLN)

Harga Freeline Therapeutics Holdings plc (FRLN) adalah $6.48

Apa kapitalisasi pasar Freeline Therapeutics Holdings plc (FRLN)

Kapitalisasi pasar Freeline Therapeutics Holdings plc (FRLN) adalah $15.41M

Pendapatan Freeline Therapeutics Holdings plc (FRLN)

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Tahun	Laba	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Laba

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Laba	Perbedaan Laba	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$3.01B	-	BE

Perusahaan

Laba

Perbedaan Laba

Negara